Home/Filings/4/0001399529-21-000116
4//SEC Filing

Ciappenelli Robert D. 4

Accession 0001399529-21-000116

CIK 0001399529other

Filed

Jun 14, 8:00 PM ET

Accepted

Jun 15, 7:19 PM ET

Size

14.5 KB

Accession

0001399529-21-000116

Insider Transaction Report

Form 4
Period: 2021-06-11
Ciappenelli Robert D.
Chief Commercial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2021-06-11$15.61/sh+10,000$156,10013,773 total
  • Sale

    Common Stock

    2021-06-11$35.00/sh10,000$350,0003,773 total
  • Exercise/Conversion

    Common Stock

    2021-06-14$15.61/sh+20,000$312,20023,773 total
  • Sale

    Common Stock

    2021-06-14$38.00/sh20,000$760,0003,773 total
  • Exercise/Conversion

    Employee Stock Option (Right to Buy)

    2021-06-1110,000290,000 total
    Exercise: $15.61Exp: 2029-06-30Common Stock (10,000 underlying)
  • Exercise/Conversion

    Employee Stock Option (Right to Buy)

    2021-06-1420,000270,000 total
    Exercise: $15.61Exp: 2029-06-30Common Stock (20,000 underlying)
Footnotes (4)
  • [F1]The Reporting Person sold an aggregate of 10,000 shares of Common Stock on June 11, 2021 (the "Shares Sold No. 1") as reported in this Form 4. The Shares Sold No. 1 represent 2.08% of 481,298 shares of Common Stock, which is the number of shares of Common Stock owned by the Reporting Person prior to the Shares Sold No. 1 transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report.
  • [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 10, 2020.
  • [F3]The Reporting Person sold an aggregate of 20,000 shares of Common Stock on June 14, 2021 (the "Shares Sold No. 2") as reported in this Form 4. The Shares Sold No. 2 represent 4.24% of 471,298 shares of Common Stock, which is the number of shares of Common Stock owned by the Reporting Person prior to the Shares Sold No. 2 transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report.
  • [F4]The option vests 25% on the first year anniversary of the vesting start date of June 3, 2019 and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date.

Issuer

Dicerna Pharmaceuticals Inc

CIK 0001399529

Entity typeother

Related Parties

1
  • filerCIK 0001778786

Filing Metadata

Form type
4
Filed
Jun 14, 8:00 PM ET
Accepted
Jun 15, 7:19 PM ET
Size
14.5 KB